Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics

Trends in Molecular Medicine

Volumn 22, Issue 4, 2016, Pages 328-340

  Bauer, Robert C ^a   Khetarpal, Sumeet A ^a   Hand, Nicholas J ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Genetics; GWAS; Lipogenesis; Triglycerides

Indexed keywords

ANGIOPOIETIN LIKE 3 PROTEIN; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; GLUCOKINASE REGULATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIPOPROTEIN LIPASE; PROTEIN; TRIACYLGLYCEROL; TRIBBLES 1 PROTEIN; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; TOLL LIKE RECEPTOR;

CORONARY ARTERY DISEASE; ENZYME ANALYSIS; ENZYME REGULATION; EXOME; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETICS; GENOME; HUMAN; HUMAN GENETICS; LIPID BLOOD LEVEL; LIPID HOMEOSTASIS; LIPID HYDROLYSIS; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROPHYLAXIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; BLOOD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HYDROLYSIS; LIVER; METABOLISM; RISK FACTOR;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CORONARY ARTERY DISEASE; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYDROLYSIS; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEINS; LIVER; MOLECULAR TARGETED THERAPY; RISK FACTORS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRIGLYCERIDES;

EID: 84960511059     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.02.005     Document Type: Review

References (104)

1. Go A.S., et al. Executive summary: heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013, 127:143-152.
2. Abifadel M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34:154-156.
3. Maxwell K.N., et al. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2069-2074.
4. Zhang D-W., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 2007, 282:18602-18612.
5. Park S.W., et al. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 2004, 279:50630-50638.
6. Cameron J., et al. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 2006, 15:1551-1558.
7. Cunningham D., et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 2007, 14:413-419.
8. Cohen J.C., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 2006, 354:1264-1272.
9. Horton J.D., et al. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 2007, 32:71-77.
10. Bergeron N., et al. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 2015, 132:1648-1666.
11. Sarwar N., et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
12. Nordestgaard B.G., et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
13. Langsted A., et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J. Intern. Med. 2011, 270:65-75.
14. Varbo A., et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. JAC 2013, 61:427-436.
15. Staniak H.L., et al. Association between postprandial triglycerides and coronary artery disease detected by coronary computed tomography angiography. Atherosclerosis 2014, 233:381-386.
16. Mortimer B.C., et al. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway. J. Biol. Chem. 1995, 270:28767-28776.
17. MacArthur J.M., et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J. Clin. Invest. 2007, 117:153-164.
18. Schwartz E.A., Reaven P.D. Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim. Biophys. Acta 2012, 1821:858-866.
19. Triglyceride Coronary Disease Genetics Consortium, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639.
20. Boekholdt S.M., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012, 307:1302-1309.
21. Do R., et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 2013, 45:1345-1352.
22. Teslovich T.M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
23. Global Lipids Genetics Consortium, et al. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 2013, 45:1274-1283.
24. Kersten S. Physiological regulation of lipoprotein lipase. Biochim. Biophys. Acta 2014, 1841:919-933.
25. CARDIoGRAMplusC4D Consortium, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet. 2013, 45:25-33.
26. CARDIoGRAMplusC4D Consortium A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat. Genet. 2015, 47:1121-1130.
27. Wittrup H.H., et al. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999, 99:2901-2907.
28. Rip J., et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1236-1245.
29. Reymer P.W., et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat. Genet. 1995, 10:28-34.
30. Carpentier A.C., et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab. 2012, 97:1635-1644.
31. Aalto-Setälä K., et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 1992, 90:1889-1900.
32. Jong M.C., et al. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J. Lipid Res. 2001, 42:1578-1585.
33. Qin W., et al. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J. Biol. Chem. 2011, 286:27769-27780.
34. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 2014, 371:22-31. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute.
35. Jørgensen A.B., et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 2014, 371:32-41.
36. Graham M.J., et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 2013, 112:1479-1490.
37. Gaudet D., et al. Targeting APOC3 in the familial chylomicronemia syndrome. N. Engl. J. Med. 2014, 371:2200-2206.
38. Gaudet D., et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N. Engl. J. Med. 2015, 373:438-447.
39. O'Brien P.J., et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 2005, 51:351-359.
40. Merkel M., et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem. 2005, 280:21553-21560.
41. Sun G., et al. Identification of lipid binding and lipoprotein lipase activation domains of human apoAV. Chem. Phys. Lipids 2006, 143:22-28.
42. Gin P., et al. The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J. Biol. Chem. 2008, 283:29554-29562.
43. Pennacchio L.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173.
44. Dorfmeister B., et al. Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1866-1871.
45. Pisciotta L., et al. Two novel rare variants of APOA5 gene found in subjects with severe hypertriglyceridemia. Clin. Chim. Acta 2011, 412:2194-2198.
46. Surendran R.P., et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J. Intern. Med. 2012, 272:185-196.
47. Johansen C.T., et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat. Genet. 2010, 42:684-687.
48. Do R., et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015, 518:102-106.
49. Kathiresan S., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 2008, 40:189-197.
50. Waterworth D.M., et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2264-2276.
51. Romeo S., et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 2009, 119:70-79.
52. Musunuru K., et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 2010, 363:2220-2227.
53. Pisciotta L., et al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. Circ. Cardiovasc. Genet. 2012, 5:42-50.
54. Robciuc M.R., et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1706-1713.
55. Shimamura M., et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 2007, 27:366-372.
56. Mattijssen F., Kersten S. Regulation of triglyceride metabolism by Angiopoietin-like proteins. Biochim. Biophys. Acta 2012, 1821:782-789.
57. Koishi R., et al. Angptl3 regulates lipid metabolism in mice. Nat. Genet. 2002, 30:151-157.
58. Köster A., et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 2005, 146:4943-4950.
59. Shimizugawa T., et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J. Biol. Chem. 2002, 277:33742-33748.
60. Wang Y., et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:11630-11635.
61. Wang Y., et al. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J. Lipid Res. 2015, 56:1296-1307.
62. Gusarova V., et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J. Lipid Res. 2015, 56:1308-1317.
63. Aulchenko Y.S., et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 2009, 41:47-55.
64. Kathiresan S., et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 2009, 41:56-65.
65. Varbo A., et al. TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population. Arterioscler. Thromb. Vasc. Biol. 2011, 31:451-457.
66. Burkhardt R., et al. Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J. Clin. Invest. 2010, 120:4410-4414.
67. Bauer R.C., et al. Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C/EBPα. J. Clin. Invest. 2015, 125:3809-3818.
68. Dedhia P.H., et al. Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia. Blood 2010, 116:1321-1328.
69. Ishizuka Y., et al. TRIB1 downregulates hepatic lipogenesis and glycogenesis via multiple molecular interactions. J. Mol. Endocrinol. 2014, 52:145-158.
70. Speliotes E.K., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011, 7:e1001324.
71. Kitamoto A., et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr. J. 2014, 61:683-689.
72. Mellinger J.L., et al. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study. J. Hepatol. 2015, 63:470-476.
73. Nagiec M.M., et al. Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of Tribbles pseudokinase 1 expression. PLoS ONE 2015, 10:e0120295.
74. Shiota C., et al. Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase. J. Biol. Chem. 1999, 274:37125-37130.
75. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316:1331-1336.
76. Lloyd D.J., et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature 2013, 504:437-440.
77. Ashton K.S., et al. Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction. 1. Discovery of a novel tool compound for in vivo proof-of-concept. J. Med. Chem. 2014, 57:309-324.
78. Xu X., et al. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin. Liver Dis. 2013, 33:301-311.
79. Baraille F., et al. Integration of ChREBP-mediated glucose sensing into whole body metabolism. Physiology 2015, 30:428-437.
80. Shih H.M., et al. Two CACGTG motifs with proper spacing dictate the carbohydrate regulation of hepatic gene transcription. J. Biol. Chem. 1995, 270:21991-21997.
81. Rufo C., et al. Involvement of a unique carbohydrate-responsive factor in the glucose regulation of rat liver fatty-acid synthase gene transcription. J. Biol. Chem. 2001, 276:21969-21975.
82. Ma L., et al. ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liver. J. Biol. Chem. 2006, 281:28721-28730.
83. Iizuka K., et al. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:7281-7286.
84. Li M.V., et al. Glucose-mediated transactivation of carbohydrate response element-binding protein requires cooperative actions from Mondo conserved regions and essential trans-acting factor 14-3-3. Mol. Endocrinol. 2008, 22:1658-1672.
85. Arden C., et al. Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes. Biochem. J. 2012, 443:111-123.
86. Li M.V., et al. Glucose-6-phosphate mediates activation of the carbohydrate responsive binding protein (ChREBP). Biochem. Biophys. Res. Commun. 2010, 395:395-400.
87. Willer C.J., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 2008, 40:161-169.
88. Kooner J.S., et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat. Genet. 2008, 40:149-151.
89. Kettunen J., et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 2012, 44:269-276.
90. Kristiansson K., et al. Genome-wide screen for metabolic syndrome susceptibility loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ. Cardiovasc. Genet. 2012, 5:242-249.
91. Chambers J.C., et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat. Genet. 2011, 43:1131-1138.
92. Nakayama K., et al. High prevalence of an anti-hypertriglyceridemic variant of the MLXIPL gene in Central Asia. J. Hum. Genet. 2011, 56:828-833.
93. Douvris A., et al. Functional analysis of the TRIB1 associated locus linked to plasma triglycerides and coronary artery disease. J. Am. Heart Assoc. 2014, 3:e000884.
94. Tennessen J.A., et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012, 337:64-69.
95. UK10K Consortium, et al. The UK10K project identifies rare variants in health and disease. Nature 2015, 526:82-90.
96. Romeo S., et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 2007, 39:513-516.
97. Quagliarini F., et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:19751-19756.
98. Peloso G.M., et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am. J. Hum. Genet. 2014, 94:223-232.
99. Wang Y., et al. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:16109-16114.
100. Orho-Melander M., et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and c-reactive protein but lower fasting glucose concentrations. Diabetes 2008, 57:3112-3121.
101. Vaxillaire M., et al. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 2008, 57:2253-2257.
102. Beer N.L., et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum. Mol. Genet. 2009, 18:4081-4088.
103. Rees M.G., et al. Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 2012, 55:114-122.
104. Rees M.G., et al. Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. Hum. Mol. Genet. 2014, 23:5570-5578.